NEW YORK, Feb. 24, 2023 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, PC, a nationally recognized shareholder rights law firm, is reminding investors that class action lawsuits may be filed on behalf of shareholders of Y-mAbs Therapeutics, Inc. YMABBioventus Inc. BVSESSTech, Inc. GWH GWH.WT))) and International Business Machines Corporation IBM. Shareholders have until the deadlines below to petition the court to be lead plaintiff. For more information on each case, see the link provided.

Y-mAbs Therapeutics, Inc. YMAB

Class period: October 6, 2020 – October 28, 2022

Lead Plaintiff Deadline: March 20, 2023

According to Y-mAbs’ Form 10-K for Fiscal Year 2021 (under 4), filed with the SEC on March 1, 2022, Y-mAbs is “a biopharmaceutical company focused on the development and commercialization of novel, antibody-based based therapeutic products for the treatment of cancer.”

According to Y-mAbs’ public statements, “Omburtamab, our lead product candidate, is a murine monoclonal antibody that targets B7-H3, an immune checkpoint molecule that is prevalent in tumor cells of various cancers. 131I-Omburtamab, which is omburtamab radiolabeled with iodine-131, is currently being evaluated in several clinical trials, including Study 101 in pivotal development and Study 03-133 in the treatment of pediatric patients with CNS/LM from NB. ” 2021 Form 10-K on 7.1

Study 03-133 included pediatric patients with neuroblastoma (NB) who had central nervous system (CNS) or leptomeningeal (CNS/LM) recurrence.

Leptomeningeal metastases occur when cancer cells have spread to thin layers of tissue covering the brain and spinal cord.

According to Y-mAbs 2021 Form 10-K (at 27), about 700 children are diagnosed with neuroblastoma (NB) in the United States each year. Of these, about 50-60% are high-risk patients, and of those high-risk patients who relapse, Y-mAbs believe that about 20% will suffer from leptomeningeal (central nervous system) metastases…